Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
Poh XY, Torres-Ruesta A, Yoong T, Wong N, Tan CW, Rouers A, Chavatte JM, Goh YS, Rao S, Chia PY, Ong SWX, Lee TH, Sadarangani SP, Lin RJH, Neo V, Kam IKJ, Huang Y, Hor PX, Loh CY; PRIBIVAC study group; Yeoh AY, Lim DRX, Chia W, Ren EC, Lin RTP, Fong SW, Renia L, Lye DC, Wang LF, Ng LFP, Young BE.
Poh XY, et al. Among authors: ren ec.
Vaccine. 2024 Nov 14;42(25):126275. doi: 10.1016/j.vaccine.2024.126275. Epub 2024 Sep 5.
Vaccine. 2024.
PMID: 39241318
Free article.
Clinical Trial.